Frontiers 22 Bergamo Session 7: When and How to Inhibit C5 in Complement-mediated Rare Nephropathies

Recorded On: 07/11/2022

  • Registration Closed
  1. Eculizumab in Primary and Secondary aHUS: Who, When, and How Long?  
  2. Eculizumab in Primary and Secondary aHUS: Who, When, and How Long?
  3. Impact of C5 Blockade on Post-transplant Outcomes and Renal Epidemiology of aHUS
  4. Oral Presentation from Abstract Selection
  5. Q&A Discussion 

Veronique Sjoerd Timmermans

Netherlands

Piero Ruggenenti

Italy

Christophe Legendre

France

Key:

Complete
Failed
Available
Locked
Session 7: When and How to Inhibit C5 in Complement-mediated Rare Nephropathies
Open to view video.
Open to view video.
You must register to access.